Back

Identifying potential drug targets for non-alcoholic fatty liver disease: a drug target Mendelian randomization study

12 April 2024 (08:30 - 14:00)
Organised by: Logo
Congress Presentation Part of: Targets and markers of cardiometabolic disease Drugs, Drug Targets CBS PREMIUM ACCESS Frontiers in CardioVascular Biomedicine 2024 Council on Basic Cardiovascular Science

About the speaker

Photo
Miss Nikita Hukerikar

University College London, London (United Kingdom of Great Britain & Northern Ireland)

1 More presentation in this session

Presentation thumbnail
Circulating levels of amyloid-beta (1-40) peptide associate with cardiometabolic traits and risk for metabolic dysfunction-associated steatotic liver disease
Doctor K. Sopova (Mannheim, DE)
Abstract

Access the full session

Session thumbnail
Targets and markers of cardiometabolic disease

The Event

Event poster

Frontiers in CardioVascular Biomedicine 2024

12 April - 14 April 2024

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources